DiaMedica Therapeutics (DMAC) EBIT (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported EBIT for 9 consecutive years, with -$10.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 31.11% year-over-year to -$10.5 million; the trailing twelve-month figure through Jun 2026 stood at -$39.2 million (down 24.71% YoY), and the FY2025 full-year result was -$34.4 million, down 28.92% from the prior year.
• EBIT steadied at -$10.5 million in Q2 2026 per DMAC's latest filing, from -$10.5 million in the prior quarter.
• Across five years, EBIT topped out at -$3.1 million in Q3 2022 and bottomed at -$10.5 million in Q2 2026.
• Historically, EBIT has averaged -$6.5 million across 5 years, with a median of -$5.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT grew 8.43% in 2022, then tumbled 64.87% in 2023.
• Over 5 years, EBIT stood at -$4.0 million in 2022, then tumbled by 47.19% to -$5.8 million in 2023, then tumbled by 43.96% to -$8.4 million in 2024, then decreased by 9.43% to -$9.2 million in 2025, then fell by 13.95% to -$10.5 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$10.5 million, -$10.5 million, and -$9.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.